A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Dato-DXdOngoingRecruitingPhase 3Open NCT06103864 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…